Annotation of CYP2D6 intermediate metabolizer
CYP2D6 intermediate metabolizer is associated with increased likelihood of Nausea, Headache, insomnia or Drug Toxicity when exposed to mirabegron in healthy individuals as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.
"Headache was the most common ADR (9 times), followed by nausea (3 times), vomiting (2 times), loose stool, palpitations and insomnia (1 time each). ""CYP2D6 IMs showed a higher ADR incidence (37.5%) than NMs (5.5%) and UMs (0%) (puv = 0.008, pmv = 0.010, OR = 9.83)."
From Publication
Genetic Variation in CYP2D6, UGT1A4, SLC6A2 and SLCO1B1 Alters the Pharmacokinetics and Safety of Mirabegron. Pharmaceutics. 2024. Soria-Chacartegui Paula et al.
Gene
Phenotype Category
Association Significance
PharmGKB ID
Score More info on scoring
Evidence for Clinical Annotations
This annotation has been used as evidence for the following clinical annotations.
Study Parameters
Study type
Study size
Association p-value
Biogeographical group More info on groups
Country
Population description
men; women; healthy individuals
Study Cohort: ADR
Note: Alleles in PharmGKB are mapped to the positive chromosomal strand. Therefore, variants in genes on the "minus" strand (eg. VKORC1) are complemented in PharmGKB annotations.
History
Loading...